TY - JOUR
T1 - Characteristics of responders to interventions for Parkinson disease
T2 - a scoping systematic review
AU - Baudendistel, Sidney T.
AU - Earhart, Gammon M.
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025
Y1 - 2025
N2 - Aims: The purpose of this review is to identify the characteristics of responders in interventions targeting motor function for individuals with Parkinson disease. Materials & methods: The primary search included, ‘Parkinson’ + ‘responder.’ A second, broader, search further included ‘response’ + ‘responsiveness’ + ‘responsive.’ Records were sorted by intervention: neuromodulation, pharmaceutical, physical, and placebo. Results: Thirteen studies were identified in the primary and 19 studies in the secondary search, culminating in 120 characteristics. For neuromodulation interventions, responders were younger at onset, more responsive to levodopa, and had more difficulties with activities of daily living. Responders to pharmaceuticals were younger at diagnosis. Physical intervention responders had worse balance, less balance confidence, and worse cognition. No relevant characteristics were identified for placebo interventions. Conclusions: Although there are clear limitations and gaps in the literature, responder analyses represent an important step toward more personalized treatments for the motor symptoms of Parkinson disease.
AB - Aims: The purpose of this review is to identify the characteristics of responders in interventions targeting motor function for individuals with Parkinson disease. Materials & methods: The primary search included, ‘Parkinson’ + ‘responder.’ A second, broader, search further included ‘response’ + ‘responsiveness’ + ‘responsive.’ Records were sorted by intervention: neuromodulation, pharmaceutical, physical, and placebo. Results: Thirteen studies were identified in the primary and 19 studies in the secondary search, culminating in 120 characteristics. For neuromodulation interventions, responders were younger at onset, more responsive to levodopa, and had more difficulties with activities of daily living. Responders to pharmaceuticals were younger at diagnosis. Physical intervention responders had worse balance, less balance confidence, and worse cognition. No relevant characteristics were identified for placebo interventions. Conclusions: Although there are clear limitations and gaps in the literature, responder analyses represent an important step toward more personalized treatments for the motor symptoms of Parkinson disease.
KW - non-responder
KW - nonresponder
KW - Parkinson
KW - responder
KW - responsiveness
UR - http://www.scopus.com/inward/record.url?scp=105004050581&partnerID=8YFLogxK
U2 - 10.1080/17582024.2025.2493465
DO - 10.1080/17582024.2025.2493465
M3 - Review article
C2 - 40304274
AN - SCOPUS:105004050581
SN - 1758-2024
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
ER -